Preliminary Data on Post Market Safety Profiles of COVID 19 Vaccines in Rheumatic Diseases: Assessments on Various Vaccines in Use, Different Rheumatic Disease Subtypes, and Immunosuppressive Therapies: A Two-Centers Study

Preliminary Data on Post Market Safety Profiles of COVID 19 Vaccines in Rheumatic Diseases: Assessments on Various Vaccines in Use, Different Rheumatic Disease Subtypes, and Immunosuppressive Therapies: A Two-Centers Study

An increased risk of developing severe infections has been evidenced in rheumatic disease (RD) patients, and anti-COVID-19 vaccination is strictly recommended for RD patients. However, up to now, no data are available on safety, immunogenicity and efficacy of COVID-19 vaccinations in RD patients. Th...

Full description

Bibliographic Details
Main Authors: Cinzia Rotondo, Francesco Paolo Cantatore, Marco Fornaro, Ripalta Colia, Giuseppe Busto, Valeria Rella, Stefania Sciacca, Lucia Lops, Daniela Cici, Nicola Maruotti, Francesca D’Onofrio, Florenzo Iannone, Addolorata Corrado
Format: Article
Language:English
Published: MDPI AG 2021-07-01
Series:Vaccines
Subjects:
rheumatic diseases
relapse
flare
disease activity
DMARDs
biologic drugs
Online Access:https://www.mdpi.com/2076-393X/9/7/730

Internet

https://www.mdpi.com/2076-393X/9/7/730

Similar Items